Prothena | PRTA - Net Income

Stock Price
10.05
Daily Change
0.19 1.93%
Monthly
7.37%
Yearly
-11.22%
Q2 Forecast
9.55

Prothena reported $-21.59M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Immunic USD -24.37M 2.99M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Prothena USD -21.59M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024